Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024
Shots:
- The P-III (REMIX-1, n=470 & REMIX-2, n=455) studies assess the safety, efficacy & tolerability of remibrutinib (25mg, BID) vs PBO for CSU inadequately controlled by 2nd-generation H1-antihistamines
- The study confirmed improvements in UAS7, ISS7 & HSS7 at wk.24 (achieved at wk.12) and showed responses during 1st wk. in patients switching to remibrutinib at wk.24 that sustained until 28wks. (end of the study). ~50% were itch & hives free (UAS7=0) at wk.52
- The remibrutinib's submission for approval in CSU to regulatory bodies worldwide is planned in H2’24. Additionally, it is being assessed for hidradenitis suppurativa (met the 1EP in P-II), food allergy, chronic inducible urticaria & multiple sclerosis
Ref: Novartis | Image: Novartis
Related News:- Novartis Reports P-III Studies (REMIX-1 & 2) Results of Remibrutinib for Chronic Spontaneous Urticaria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
